Request Demo

Last update 08 May 2025

Jaw osteitis

Last update 08 May 2025

Basic Info

Synonyms

Jaw osteitis, Osteitis - jaw, Osteitis of jaw

+ [7]

Introduction-

Drugs associated with Jaw osteitis

Cefcamate Pivoxil Hydrochloride

Target

PBPs

Mechanism

PBPs inhibitors [+1]

Active Org.

Shionogi & Co., Ltd. [+1]

Originator Org.

Shionogi & Co., Ltd.

Active Indication

Bacterial Infections [+30]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Japan

First Approval Date22 Apr 1997

Clinical Trials associated with Jaw osteitis

JPRN-UMIN000046014

/ SuspendedNot ApplicableIIT

Examination of the effect of hainosankyuto on chronic osteomyelitis of the jaw - The effect of hainosankyuto on chronic osteomyelitis

Start Date01 Oct 2023

Sponsor / Collaborator-

CTR20223292

/ CompletedNot Applicable

浙江麒正药业有限公司研制的西他沙星片与持证商为Daiichi Sankyo Co., Ltd的西他沙星片（商品名：格雷必妥®/GRACEVIT®）在中国健康受试者中进行的随机、开放、单剂量、两周期、双交叉、空腹及餐后状态下的生物等效性研究

[Translation] A randomized, open-label, single-dose, two-period, double-crossover, fasting and fed bioequivalence study of sitafloxacin tablets developed by Zhejiang Qizheng Pharmaceutical Co., Ltd. and sitafloxacin tablets (trade name: GRACEVIT®) from Daiichi Sankyo Co., Ltd in healthy Chinese subjects

以浙江麒正药业有限公司研制的西他沙星片（规格：50 mg）为受试制剂，以持证商为Daiichi Sankyo Co., Ltd的西他沙星片（商品名：格雷必妥®/GRACEVIT®，规格：50 mg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性；同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

Sitafloxacin tablets (specification: 50 mg) developed by Zhejiang Qizheng Pharmaceutical Co., Ltd. were used as the test preparation, and Sitafloxacin tablets (trade name: GRACEVIT®/GRACEVIT®, specification: 50 mg) from Daiichi Sankyo Co., Ltd were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent; at the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date07 Feb 2023

Sponsor / Collaborator

Zhejiang Qizheng Pharmaceutical Co., Ltd

CTR20221713

/ CompletedNot Applicable

西他沙星颗粒（50mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of sitafloxacin granules (50 mg) in Chinese healthy subjects under fasting and fed conditions

主要研究目的：按有关生物等效性试验的规定，选择第一三共株式会社为持证商的西他沙星颗粒（规格：10%（30g））为参比制剂，对济川药业集团有限公司生产的受试制剂西他沙星颗粒（规格：50mg）进行空腹和餐后给药生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，比较两种制剂在空腹和餐后给药条件下的生物等效性。次要研究目的：观察健康志愿受试者口服受试制剂西他沙星颗粒（规格：50mg）和参比制剂西他沙星颗粒（规格：10%（30g））的安全性。

[Translation]

Main research purpose: According to the relevant provisions of bioequivalence test, the sitafloxacin granules (specification: 10% (30g)) of Daiichi Sankyo Co., Ltd. as the licensee was selected as the reference preparation, and the test preparation sitafloxacin granules (specification: 50mg) produced by Jichuan Pharmaceutical Group Co., Ltd. were subjected to fasting and postprandial bioequivalence test to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to compare the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation sitafloxacin granules (specification: 50mg) and the reference preparation sitafloxacin granules (specification: 10% (30g)) by healthy volunteers.

Start Date07 Aug 2022

Sponsor / Collaborator

Hubei Jumpcan Pharmaceutical Co., Ltd.

100 Clinical Results associated with Jaw osteitis

100 Translational Medicine associated with Jaw osteitis

0 Patents (Medical) associated with Jaw osteitis

300

Literatures (Medical) associated with Jaw osteitis

01 Apr 2025·RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren

Bone Tumors of the Jaw – the “Blind Spot” for Radiologists Experienced with Tumors? – Part I

Review

Author: Grieser, Thomas ; Hirsch, Edgar ; Tödtmann, Ninette

AbstractPrimary bone tumours of the jaw are rare tumoral entities and do substantially differ from other bone tumours of the human body with respect of their frequently encountered unusual radiological appearances. The reason for that may be confined to the co-existence of two closely neighbored but different anatomical structures (i.e., tooth-forming apparatus and jaw bones with adjacent gingiva) and some tumour pathologies which are nearly excusively encountered in the jaw bones only (e.g., ameloblastoma, ossifying fibroma, ghost cell carcinoma).This paper would like to highlight some basic principles of the diagnostic approach and possibilities of radiological differentiation of such tumour-suspicious changes within the gnathic system are elucidated and discussed.The paper presented here is substantially based on the most recent classification of odontogenic and maxillofacial tumours (5th edition, 2022) which serves as a scaffold for the selection of typical tumour entities. Due to the educational character of this paper, only important jaw tumours worth mentioning and their characteristics are subject to be extracted from the literature and further discussed.The main focus was put onto both the description of radiological tumoral appearance and the rational selection of a radiological diagnostic work-up. In order to better visualize this difficult field of tumour entities, much attention has been paid on a comprehensive pictorial essay.For radiologists, it is their foremast task to detect, describe, and to classify bone tumours of the jaw when they are found intentionally or accidentally, resp. A close co-operation with their clinical partners is of upmost importance to gain information about patient’s history and clinical presentation. It is readily reasonable that radiologists are mostly able to provide only a suggestion of the presented tumour entity but this expert opinion would be very helpful to further narrow down the list of potential differential diagnoses (e.g., differentiation of a cyst vs. solid tumour osteolysis, identification of jaw osteomyelitis vs. tumoral infiltration, recognizing of secondary tumour involvement of the jaw).

01 Jan 2025·Ear, Nose & Throat JournalQ4 · MEDICINE

A case of bisphosphonate-related osteonecrosis of the maxilla with orbital cellulitis

Q4 · MEDICINE

ArticleOA

Author: Matsuno, Hideo ; Ikeda, Katsuhisa ; Tajima, Shori ; Matsumoto, Fumihiko

Bisphosphonates are used for the treatment of bone metastases of cancer and prevention of osteoporosis. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) has unclear mechanisms, but its elucidation, prevention, and treatment are essential to improve patient outcomes. An 88-year-old woman who was taking oral bisphosphonates for 4 years presented with a 5-day history of gradual orbital pain. Computed tomography (CT) revealed bilateral maxillary sinusitis and bony destruction at the base of the right maxillary sinus and inferior orbital wall. We diagnosed her with bisphosphonate-related osteonecrosis of the maxilla. In addition to intravenous antibiotic treatment, an endoscopic sinus surgery was performed. The patient’s postoperative course was uneventful. To the best of our knowledge, this is the first case report of BRONJ with orbital cellulitis. This condition should be considered among patients taking bisphosphonates, who manifest with symptoms of orbital cellulitis and bone destruction on imaging.

01 Jan 2025·Journal of Clinical and Experimental Dentistry

Chronic Osteomyelitis of the Jaw. Osteomyelitis

Review

Author: Mateos-Moreno, María Victoria ; Madrigal-Martínez-Pereda, Cristina ; López-Carriches, Carmen ; Taheri, Ricardo ; López-Quiles Martínez, Juan

BackgroundChronic osteomyelitis of the jaw is an inflammatory reaction of bone tissue of infectious origin that affects the medullary cavity. The main causes of osteomyelitis are odontogenic or traumatic.Material and MethodsBibliographic research, the following electronic databases have been searched: Pubmed Medline and the Chochrane Library Plus.ResultsClinical symptoms are pain, inflammation, suppuration, intraoral or extraoral drainage fistulas. Bone and soft tissues that do not respond favorably to treatment, potentially can lead to bone sequestra. Diagnosis should include a histopathological study throughout a proper biopsy. Identifying the responsible microorganisms is not easy, as the sample can be contaminated by nearby sites. However, a presumptive diagnosis can be made through clinical and radiographic evaluation. Treatment for osteomyelitis involves eliminating the source of infection and necrotic tissue, establishing drainage, restoring blood supply, and controlling the infection with appropriate antimicrobial therapy. Broad-spectrum antibiotics like penicillin or clindamycin are often prescribed initially, but the regimen may be adjusted based on the microbiological findings.ConclusionsLong-term antibiotic therapy is generally required, ranging from 4 to 6 weeks, depending on the severity and chronicity of the infection. Key words:Chronic Osteomyelitis, antibiotic, mandible, microbiology, surgery.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Jaw osteitis

Basic Info

Related

Analysis